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The advent of next-generation sequencing (NGS) has revolutionised public health microbiology. Given the potential
impact of NGS, it is paramount to ensure standardisation of ‘wet’ laboratory and bioinformatic protocols and promote
comparability of methods employed by different laboratories and their outputs. Therefore, one of the ambitious goals
of the Global Microbial Identifier (GMI) initiative (http://www.globalmicrobialidentifier.org/) has been to establish a
mechanism for inter-laboratory NGS proficiency testing (PT). This report presents findings from the survey recently
conducted by Working Group 4 among GMI members in order to ascertain NGS end-use requirements and attitudes
towards NGS PT. The survey identified the high professional diversity of laboratories engaged in NGS-based public
health projects and the wide range of capabilities within institutions, at a notable range of costs. The priority pathogens
reported by respondents reflected the key drivers for NGS use (high burden disease and ‘high profile’ pathogens). The
performance of and participation in PT was perceived as important by most respondents. The wide range of sequencing
and bioinformatics practices reported by end-users highlights the importance of standardisation and harmonisation of
NGS in public health and underpins the use of PT as a means to assuring quality. The findings of this survey will guide
the design of the GMI PT program in relation to the spectrum of pathogens included, testing frequency and volume as
well as technical requirements. The PT program for external quality assurance will evolve and inform the introduction of
NGS into clinical and public health microbiology practice in the post-genomic era.
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StandardsBackground
The advent of next-generation sequencing (NGS) tech-
nologies has revolutionised molecular microbiology by
making genome sequences of pathogens of clinical or
public health importance, readily available [1]. NGS has
many advantages over other existing molecular ap-
proaches, including throughput, quality, flexibility, scalabil-
ity and thus may potentially replace a multitude of assays
currently run simultaneously in a diagnostic microbiology
laboratory [2,3].* Correspondence: rshe@food.dtu.dk
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unless otherwise stated.Translation of NGS from research centres to public
health and clinical laboratories has already begun. As
the technology becomes less expensive and turnaround
times shorten, expansion of NGS into diagnostic practice
is expected to be rapid. The first significant role for
NGS is likely to be in the communicable disease surveil-
lance and outbreak investigations [4]. Recent studies
have demonstrated that SNPs mined from whole gen-
ome sequence (WGS) data [5-7] as well as gene-by-gene
(core genome multi-locus sequence typing (MLST) [8])
comparisons provided far greater resolution for outbreak
detection and for microbial strain tracking for a wide
range of bacterial pathogens than current gold standards
such as pulsed-field gel electrophoresis (PFGE), spoligo-
typing, and variable number tandem repeat-based typing.
Additionally, the growth of public databases harbouringntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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NGS in public health and in clinical practice [9,10].
Thus NGS technologies will undoubtedly improve mo-
lecular epidemiology studies, public health laboratory
surveillance and communicable disease control in the
future [11-13].
This paradigm shift in clinical diagnostics and surveil-
lance of microorganisms as a result of the rapid develop-
ment of inexpensive NGS technologies and continuing
increase in computing power and data-transport capacity
will impact microbiology in clinical laboratories, hospi-
tals and other public health institutions. Ideally, it will
also enable all countries to detect current and emerging
infectious diseases in real-time and at low cost and share
information in a standardised manner [14]. Thus, an ini-
tiative was started in September 2011 by several infec-
tious disease control centres and other organisations
with the first meeting convened in Brussels formulating
the overall goal [15]; A global system to aggregate, share,
mine and translate genomic data for microorganisms in
real-time [14]. Since then, the initiative has grown and is
today composed by over 150 experts from around 30
countries. Subsequently, the initiative was named; the
Global Microbial Identifier (GMI) and a Steering Com-
mittee was established as well as five working groups.
Given the expectation for a growing reliance on NGS
technologies in clinical and public health laboratories it
is paramount to understand and assess the robustness of
results from different methodologies in order to enhance
standardisation of ‘wet’ laboratory and bioinformatics
analyses and promote comparability [16]. Therefore, one
of the goals of the GMI initiative is to establish a formal
mechanism for inter-laboratory test performance to
ensure harmonisation and standardisation in WGS and
data analysis. In February 2013 at the GMI initiative’s
5th meeting in Copenhagen Denmark, a visionary taskforce
of scientists and other stakeholders met, sharing an aim
of making novel genomic technologies and bioinfor-
matics tools available for improved global patient diag-
nostics, surveillance and research, by developing data
exchange and analysis tools for characterisation of all
microbial organisms and microbial communities.
During this meeting, the GMI Working Group 4
(WG4) was established to coordinate the GMI sponsored
proficiency testing (PT) exercises. By having multiple la-
boratories perform NGS on a set of well-characterised
strains, the results produced by the different laboratories
will be used to identify those steps in the process where
QA/QC (quality assurance/quality control) measures need
to be taken to increase the concordance among results
and harmonise the interpretation of data. To ensure any
PT exercise was aligned with the expectation of the GMI
end-users, a survey was developed to identify the types of
end-user, the priority test organisms and quality markersto be measured. This report outlines the results of this
survey of GMI members (survey available as supplemen-
tary file) in relation to their current capabilities, require-
ments for and attitudes towards performance of PT.
Methods
With the aim to ensure harmonisation and standardisation
in WGS and data analysis, WG4 developed a survey using
the online survey software (https://www.surveymonkey.
com/) for the collection of relevant information from sci-
entists based in institutes and organisations from different
parts of the world (supporting information). It included
questions within three main topics with responses allowing
for: 1) identification of potential end users of a PT, 2) iden-
tification of target organisms to be sequenced during a PT,
and 3) establishment of quality assessment procedures to
be implemented in the PT. Differences in responses within
an organisation were likely to be observed and therefore re-
spondents were encouraged to submit data as individuals/
research groups within institutions. The respondents were
encouraged to submit information on their needs and cap-
acity in relation to DNA preparation, sequencing, and ana-
lysis (e.g. variant detection and clustering) enabling the
organisers to take this information into consideration when
creating the PT and in the work towards standardised test-
ing and quality assurance of these tests.
The questionnaire contained 35 items, provided in
three sections, including information on end-users (per-
sonal and organisational information), characterisation
of target organisms and quality assessment. Specifically,
information was sought regarding the institutional pro-
file of respondents, capability and capacity of performing
NGS, institutional priorities for NGS, attitudes towards
a PT for NGS, operational aspects of delivering a PT for
NGS and finally a survey of current technical NGS and
bioinformatics practices. The responses were collected
as free text or single options from pre-defined drop-
down lists. Some responses were measured on a 5-point
Likert-type scale with anchors specific to the question
(e.g., 1 = strongly agree; 2 = agree; 3 = unsure; 4 = dis-
agree; 5 = strongly disagree). Pilot testing was done with
WG4 members to determine the acceptability and clarity
of the questionnaire. The questionnaire is available as an
appendix to this report.
Invitations to participate in the survey were sent to
members of the Global Microbial Identifier initiative
worldwide (N = 155) with a link directing to the online
survey. No monetary incentive was offered. The invita-
tion included information that responses would be kept
confidential and would be anonymised prior to inclusion
in a published report. The survey was available online
for a two month period during which electronic invitations
and reminders were sent to those who had not responded.
Respondents were invited to send any questions or
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In all, 47 responses were registered in the system. Fol-
lowing de-duplication, 45 responses were eligible for
analysis, representing an overall survey response rate of
29%. The distribution of respondent’s country of origin
was as following: United States (n = 14, 31.1%), United
Kingdom (n = 7, 15.6%), Denmark (n = 4, 8.9%), Canada
(n = 4, 8.9%), Germany (n = 3, 6.7%), France, Malaysia,
Italy and Sweden (n = 2, 4.4%) and Spain, Israel, Poland,
Finland and Australia (n = 1, 2.2%). The 45 respondents
represented 39 organisations; one institution was repre-
sented by three respondents, four institutions were rep-
resented by two respondents and 34 institutions by a
single respondent.
Survey respondents represented the following sectors
(multi-sectoral designation was allowed): governmental
(n = 26, 58%), public health (n = 25, 56%), research (n =
24, 53%), university (n = 12, 26.7%), food (n = 11, 24.4%),
animal (n = 8, 17.8%), private ownership (n = 7, 15.5%),
and plant / environment (n = 5, 11.1%). The reported
roles of respondents within their institutions (multiple
roles were allowed) included: academic / researcher (n = 27,
60%), laboratory scientist / microbiologist (n = 15, 33.3%),
bioinformatician (n = 13, 28.9%), public health professional/
epidemiologist (n = 10, 22.2%), clinician (n = 3, 6.7%) and
infection control practitioner (n = 1, 2.2%). Notably, twoTable 1 Access to NGS platforms as internal or external infras
NGS Platform Number having any access
Ion Torrent PGM 23
Ion Torrent Proton 6
GS Junior System (454) 9
Genome Sequencer FLX (454) 12
PacBio RS 8






Genome Analyzer lIx 9
MiSeq Benchtop Sequencer 36
ABI SOLiD 6
other 1
Total 152respondents identified themselves as post-graduate students
(4.4%). Three respondents were representatives of commer-
cial sequencing companies (6.7%) and were excluded from
further analysis, which thus included 42 respondents in
total.
Capability and capacity
The majority of respondents had appropriate arrangements
in place for shipping microorganisms or DNA (85.7% and
95.2%, respectively) while 64.3% had arrangements for gen-
omic data transfer (Additional file 1: Figure S1). All but
one respondent were currently performing NGS and bio-
informatics analysis. Internal NGS capability was reported
by 84% whereas external access to NGS was reported by
57% (Additional file 1: Figure S2a). Only 14% of respon-
dents were solely dependent upon external NGS services.
With regard to bioinformatics, 88% had internal capability
whereas only 10% were solely dependent upon external
services (Additional file 1: Figure S2b). Forty respondents
reported having access to the currently available NGS tech-
nologies, consisting of a total of 152 different NGS plat-
forms cumulatively reported. The distribution across NGS
technologies is depicted in Additional file 1: Figure S3.
Accessibility to different platforms internally or exter-
nally is shown in the Table 1. The three most commonly
accessible platforms were MiSeq (23.7%), Ion torrent
PGM (15%) and HiSeq 2500 (10.5%). These three plat-
forms accounted for 60.8% of internally accessible se-
quencers and 30.1% of externally accessible sequencers.
Out of 44 NGS platforms available in participating insti-
tutions and specifically intended by respondents for use
during a PT for NGS, Illumina MiSeq, Ion Torrent PGMtructure

















Moran-Gilad et al. BMC Infectious Diseases  (2015) 15:174 Page 4 of 10and HiSeq 2500 accounted together for 81.8% of in-
stances (24, 9 and 3 out of 44, respectively). The
remaining were older HiSeq models (3), PacBio (3), GS
454 FLX (1) and Ion torrent proton (1).
Any information regarding the costs of running NGS
using different platforms was provided by 33 out of 42
respondents (78.6%). The reported costs of sequencing a
single bacterial genome of 5 MB at coverage 20X and
maximum multiplexing were as shown in Additional file
1: Table S1. In the majority of cases (57 out of 75, 76%),
sequencing of a single bacterial genome was reported to
cost less than US$ 500 at the time of survey. At this
cost, sequencing was achieved internally in 48 of 59 plat-
forms (81.3%) as opposing to 9 of 16 platforms exter-
nally (56.2%, p = 0.1).
The volume of NGS for bacterial genomes performed
annually by respondents is summarized in Additional file
1: Table S2. Of 70 NGS ‘jobs’ reported, 5.7% involved up
to 10 genomes and 8.6% over 2,000 genomes. Volume of
up to a 100 genomes per year accounted for 75% of ex-
ternal sequencing jobs but only 24.1% of internal se-
quencing jobs (p < 0.005, OR = 9.46). Sequencing by
Illumina technology accounted for 13 / 25 (52%) of jobs
involving up to 100 genomes and 31 / 45 (68.9%) of ex-
periments involving over 100 genomes (p = 0.16). Never-
theless, 100% of the 23 NGS ‘jobs’ involving >500
genomes were performed using Illumina technology.Sequencing priorities
Information regarding priority pathogens most fre-
quently processed by participating institutions was pro-
vided by 34 of 42 respondents. For five categories
allowed, a total of 142 pathogens were listed (34 respon-
dents listed at least one category of the most frequently
processed pathogen while 23 listed all five priorityTable 2 Agreement with possible evaluation criteria of PT for
Statement
17.1 Assessment of the quality of WGS reads is a very important consideratio
17.2 Ability to integrate and accommodate sequence data from multiple ven
platforms is a very important consideration
17.3 Capacity for de novo sequencing and genome assembly is a very impor
consideration
17.4 Capacity for analysis of emerging biothreats is a very important conside
17.5 Accurate classification of existing frequently tested and globally relevant
pathogens (e.g., foodborne Salmonella) is a very important consideration
17.6 Quality of reference based assembly is a very important consideration
17.7 Quality of annotation is a very important consideration
17.8 Single nucleotide polymorphism (SNP) calls is a very important consider
17.9 Tree building is a very important considerationcategories). The taxon distribution of the first category
appears in Additional file 1: Figure S4a. Notably, three
out four pathogens most frequently sequenced were
foodborne pathogens (Additional file 1: Figure S4b). The
frequency of taxons sequenced over the passing year by
respondents is shown in Additional file 1: Figure S4c.
Top 5 sequenced pathogens were again the leading food-
borne pathogens and S. aureus.
The reasons for using NGS were reported by 41 respon-
dents, according to 11 provided application categories
using a 1-5 scale (1 – most important, 5 - least important).
The average scores for the 11 categories are shown in
Additional file 1: Figure S5a. The leading indication was
by far high resolution clustering for outbreak investigation
(mean score 1.6) whereas metagenomics, pathogen discov-
ery and evolutionary microbiology were perceived as least
important (mean scores >3 points). The consideration in
selecting pathogens for using NGS were reported by 41
respondents, according to 9 provided application categor-
ies using a 1-5 scale (1 – most important, 5 - least import-
ant). The average scores for the 11 categories are shown
in Additional file 1: Figure S5b. The leading consideration
was by far a high impact on public health (mean score
1.69) followed by utility for performing real time labora-
tory surveillance (mean score 2.32).
Attitudes towards proficiency testing for NGS
None of the 41 respondents strongly disagreed with any
of the nine statements concerning the evaluation criteria
for PT for NGS (Table 2). Over 75% of respondents
expressed agreement or strong agreement with all nine
statements. In particular, accurate classification of
existing frequently tested and globally relevant patho-
gens (e.g., foodborne Salmonella) as well as phylogen-
etic tree building were statements with which >90%
agreed or strongly agreed. Any disagreement was notedNGS
Strong disagreement Strong agreement % agreement
n 0 2 4 15 20 85.4%
dor 0 2 4 17 18 85.4%
tant 0 3 6 21 11 78%
ration 0 0 11 19 11 73.2%
0 0 3 22 16 92.7%
0 3 6 20 12 78%
0 2 8 24 7 75.6%
ation 0 2 4 15 20 85.4%
0 0 4 24 13 90.2%
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10%.
Operational aspects of PT for NGS
Respondents were asked to delineate five priority patho-
gens for inclusion in the PT for NGS that will look at all
stages of sequencing and analysis processes. Based on 24
respondents providing this information, Salmonella was
by far the top priority for NGS PT, listed by 9 respon-
dents, followed by S. aureus and RNA viruses (3 each),
L. monocytogenes, M. tuberculosis and E. coli (2 each)
and influenza virus, Campylobacter spp. and C. difficile,
(1 each). When prioritisation was generated after pool-
ing all five priority categories reported (Figure 1), the
leading pathogens were Salmonella (17%), E. coli (14%)
and Campylobacter spp. (12%), followed by S. aureus
(9%) and L. monocytogenes (8%). Respondents were also
asked to delineate five priority pathogens for inclusion
in a PT for NGS carried out by provision of simulated
datasets for bioinformatics analysis. Based on 26 respon-
dents providing this information, Salmonella was again
the top priority for NGS PT, listed by 9 respondents,
followed by S. aureus (4), E. coli (3), RNA viruses, L.Figure 1 Priority pathogens for inclusion in PT for NGS sequencing anmonocytogenes, M. tuberculosis and Enterobacteriaceae
(2 each) and influenza virus and Campylobacter spp.
(1 each). When prioritisation was generated after pool-
ing all five priority categories (Figure 1), the leading patho-
gens were E. coli, Salmonella and Campylobacter spp.
followed by L. monocytogenes, M. tuberculosis and S.
aureus.
With regards to the number of different strains to be
used in the PT, per dispatch, 36 respondents displayed
the following preferences (Additional file 1: Table S4):
39.4%, 57.6% and 53.1% of respondents regarded PT
samples containing viruses, fungi and protozoa as not
relevant, as compared to only 8.3% for bacterial PT. A
substantial proportion of respondents were willing to
process 4 bacterial PT samples per dispatch (44.4% for
strains, 47.2% for DNA and 50% for genomic datasets).
Of those interested in viral PT, 60% were willing to
process 4 samples per dispatch.
NGS and bioinformatics practices
The survey of current technical NGS and bioinformatics
practices and usage included a series of 15 questionnaire
items with a varying response rate. The intended use ofd NGS bioinformatics analysis.
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in Figure 2. NGS was used commonly for de novo se-
quencing, resequencing, metagenomics and RNA se-
quencing. Two respondents highlighted data would be
used to create public health policy or develop bioinfor-
matics tools. For library preparation, a notable diversity
in methods used was reported among 39 respondents
with transposon-based fragmentation being the most
common method, followed by physical shearing and en-
zymatic shearing (Additional file 1: Figure S6). In
addition, 74.3% reported multiplexing of samples in
NGS runs was being performed. Notably, 29% reported
not to be performing hands-on library preparation. Im-
portantly, only 46.7% of respondents (35.9% overall)
were routinely including standard or reference materials
in their NGS runs.
The commonly expected coverage while performing
NGS for bacteria was 31-60X (51.3% of respondents)
and coverage of 11-30X or over 60X was reported by
21.6% and 18.9%, respectively (Additional file 1: Table
S5). Of those performing NGS for viruses, 12 out of 17
(76%) were working at coverage of >60X. Very few were
performing practical NGS for fungi and protozoa, with
results varying.
The genomic information intended to be captured
from NGS data analysis was diverse (Figure 3). SingleFigure 2 Intended use of NGS data.nucleotide polymorphisms (SNPs) and locus-specific
variations were the most commonly expected outputs of
NGS analysis (90% and 85%, respectively), followed by
mobile genetic elements and insertions/deletions (indels)
(77.5% each). Of 29 respondents, 86.2% reported low-
quality base trimming during bioinformatics analysis.
Those few not performing trimming reported it was ei-
ther not necessary for their intended use, performed
automatically by their NGS software or will consider
trimming in future analyses.
The vast majority of respondents perceived quality
filtering as important to any extent (92%) and 56%
very important (Additional file 1: Figure S7). In
addition, of 34 respondents performing assemblies of
NGS data, 73.5% reported having any established cri-
teria for quality assessment and quality control of as-
semblies. Most of the 25 respondents reporting
having quality criteria for assemblies in place
employed more than one criterion. The frequency of
various criteria is shown on Additional file 1: Figure
S8. The most commonly used criterion was coverage
(90.9%) followed by number of bases and mapping of
reads to reference (68.2% each). When respondents
were asked to provide values for quality criteria, a
wide variety of responses was noted and no conclu-
sions could be drawn.
Figure 3 Genomic information intended to be captured from NGS.
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Additional file 1: Figure S9. Of 35 respondents, 71%
stated they used mainly or exclusively externally de-
veloped software whereas 23% relied mainly but not
exclusively on internally developed software. In 6%
analyses were done elsewhere. Of those 35, 32 re-
spondents also provided information regarding spe-
cific assembly software being used. The leading
software was Velvet (75%), Newbler (46.9%) and CLC
(46.9%) and SOAPdenovo (25%). Other software used
by less than 20% of users included ABySS, ALLPATHS-
LG, CABOG, Edena, Euler, Mira, MSR-CA, SGA, SSAKE,
VCAKE, SPAdes, Cortex, CloVR, RAST, Geneious and
SAMtools.
Thirty respondents provided information regarding
specific mapping software packages being used. The
leading software was BWA (66.7%), Bowtie 2 (53.3%)
and Bowtie 1 (23.3%). Other software used by 10% of
users included Novoalign and SMALT, while BFAST,
MAQ, SHRiMP, SSAHA2, tmap and Geneious were used
by less than 10%.
Discussion
The WGS data is worth more if it is shared globally in
an open source manner and linked to clinical and epi-
demiological contexts (e.g., informative metadata). Not-
ably, pioneering studies to inform implementation of
NGS based real-time prospective surveillance and ana-
lysis of foodborne pathogens such as Listeria monocyto-
genes and Salmonella enterica are underway in leadinginstitutions throughout North America and Europe.
Moreover, the use of NGS for near real-time investiga-
tion of probable transmission pathways has already been
reported [6,17-19].
As WGS is applied to public health surveillance, stan-
dardising quality metrics becomes critical. These metrics
include, for example, standards for calibration, valid-
ation, and comparison among platforms; data reliability,
robustness, and reproducibility, and the quality of as-
semblers [3,16]. Like any technology, WGS has its ad-
vantages and limitations. Potential uncertainties and
errors can be introduced into the sequence analysis by
the sequencing machines, analytical algorithms and re-
sidual errors in the reference data with what we align
the new sequence. Thus proficiency testing programs
that cover both sequencing “wet lab” and analytical “dry
lab” steps are urgently required. To our knowledge, this
is the first review of the current state of play, needs and
priorities in relation to the proficiency testing for WGS
performed in the field of microbiology.
Key findings
The current report illustrates current NGS and bioinfor-
matics capability and practice within the GMI commu-
nity and attitudes towards the setting up and delivery of
a PT programme for NGS. Our survey highlights the
professional diversity of individuals engaged in NGS-
based projects and the wide range of capabilities within
institutions. For example, some institutions are currently
performing NGS on a limited basis, mainly by relying on
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stitutions are running large scale NGS studies with in-
ternal sequencing and computational infrastructures.
This diversity is also associated with a notable range of
costs per sample.
The priority pathogens reported by respondents that
are being investigated with NGS represent the entire
gamut of foodborne illness, with emphasis on the patho-
gens associated with highest disease burden in humans,
followed by ‘high profile’ non-foodborne pathogens of
clinical and public health importance such as M. tuber-
culosis, S. aureus and RNA viruses. This is in agreement
with the fact that key outputs expected from NGS are of
use in molecular epidemiology, high resolution typing
and outbreak investigation.
For most end-users, the performance of and participa-
tion in PT was perceived as important. Information col-
lated through this survey will help guide the PT in terms
of the pathogens included, PT frequency and technical
requirements. The wide range of sequencing and bio-
informatics practices reported by end-users highlights
the importance of standardization and harmonisation of
NGS in public health and underpins the use of PT as a
means to assuring quality.
Quality consideration for NGS in microbiology
There are significant differences in the sequencing
methods, specimen preparation, run throughput and
hands-on time between different sequencing platforms.
In addition, the amount of sequencing data sufficient for
pathogen characterisation (i.e. genome ‘coverage’) and
associated outbreak investigations remains the subject of
debate [1,20]. These variables may have technology- and
coverage-specific effects on the detection of genomic
variants. Thus laboratories are expected to balance the
pathogen genome characteristics, the instrument through-
put, the accuracy of variant-calling algorithms and the
cost of sequencing runs.
The outputs generated by different sequencing plat-
forms are subjected to multiple analytical steps that usu-
ally start with sequence assembly or reference-based
mapping and finish with simultaneous comparisons of
multiple genomes and data visualisation. Bioinformatic
approaches for genome-wide analyses of pathogens are
highly varied across the microbiology community, with
an abundance of tools continually being developed, re-
fined and packaged together as software ‘pipelines’ [21].
Whilst NGS based surveillance is expected to become
common in the near term [3], identification of patho-
gens, rather than traceback investigations, is likely to be
among the last areas where NGS becomes routine as the
cost are high and other technologies such as qPCR and
MALDI-TOF are effective. However, the technology
could be employed to detect yet unknown, emerging orfastidious pathogens. Furthermore, deep sequencing would
allow in the near future, identification of pathogens from
primary clinical samples and/or to characterize the normal
microbiota and pathogenic flora of non-sterile body sites
using meta-genomic strategies.
Impact of survey outputs on envisaged PT for NGS
Principles of NGS standardisation for clinical testing
have been recently outlined by a national working group
on laboratory medicine convened by the US Centers for
Disease Control and Prevention [16]. Their recommen-
dations emphasise the need for adequate validation,
quality control, use of reference materials and perform-
ance of independent PT. In agreement with such recom-
mendations, GMI is currently executing a pilot PT
scheme with intended full roll-out in ultimo 2014. The
main objective of this PT is to ensure harmonisation
and standardisation in whole genome sequencing and
data analysis, with the aim to produce comparable data
for the GMI initiative. A further objective is to assess
and improve the uploaded data to databases such as
NCBI, EBI and DDBJ. Therefore, the laboratory work
analysis performed for this PT should be done by using
the methods routinely used in the individual laboratories.
The PT will consist of two wet-lab and one dry-lab
component(s) targeting priority microorganisms such as
Salmonella, E. coli and S. aureus. The PT will emphasise
NGS applications in microbiology highlighted by the
survey (e.g. SNP analysis). The wet-lab components to
be provided, will assess the laboratories ability to perform
DNA preparation, sequencing procedures and analysis of
epidemiological markers whereas the dry component will
assess the laboratories’ ability to analyse a whole-genome-
sequencing dataset and distinguish between clonally re-
lated and sporadic genomes. In order to achieve this, the
PT substrates will be provided to participants via transport
of lyophilised live cultures and stabilized bacterial DNA
distributed by courier and electronic fastq datasets pro-
vided through ftp servers. All PT stages will follow stan-
dardised procedures.
Study limitation
These conclusions should be interpreted in light of the
limitations in the study design. First, the survey relied
on self-reported behaviour without verification that par-
ticipants actually practiced in the manner described.
Second, we surveyed only GMI participants. Scientists in
the developing world are likely to differ from developed
world practitioners in their technology use and in infor-
mation needs. However, this has the advantage of repre-
senting the point of view of professionals who are
usually “early adopters” of new concepts and the opinion
leaders in their field. Third, there may be a volunteer
bias related to the fact the those community member
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increased interest in moving into NGS were more likely
to sign up to the survey.
Conclusions
The significant variation in the use of NGS and data ana-
lytics in public health microbiology and differences in atti-
tudes of microbiologists deserve careful consideration.
Important for the reliability of submitted sequence data to
a GMI database and other public sequence archives will be
the test of the congruence of outputs among members’ in
DNA extraction, library preparation, the actual sequen-
cing, assembly and phylogenetic analysis following differ-
ent laboratory protocols, software tools, and platforms
[16,21]. GMI aims to assist laboratories and partners glo-
bally to perform NGS to the highest degree of quality. The
findings of our survey will guide the PT activities of the
GMI to ensure it meets the expectations of the end-users.
In addition we have gathered information on capability, at-
titudes and practices of GMI community members. It is
envisaged that PT of WGS in microbiology will be a dy-
namic process that will continuously evolve and, thereby,
inform the introduction of NGS into clinical and public
health microbiology practice and will inevitably become
the routine tool for external quality assurance in the post-
genomic era.
Additional file
Additional file 1: Table S1. Costs of bacterial NGS by platform as
reported by respondents at time of survey. Table S2. Volume of
bacterial NGS performed annually by respondents. Table S3. Preferred
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